PRIMARY OBJECTIVES:~I. To determine the proportion of patients requiring intubation/ventilator support, requiring rescue with tocilizumab, or dying.~II. To determine 1 month survival.~SECONDARY OBJECTIVES:~I. To estimate the safety and tolerability of dasatinib anhydrous (dasatinib) in the setting of COVID-19 infection.~II. To determine change in C-reactive protein (CRP) levels after starting therapy.~III. To document activity of dasatinib in lessening cytokine release syndrome (CRS) and sequential organ failure assessment (SOFA) score.~EXPLORATORY OBJECTIVES:~I. Interleukin-6 /cytokine assay weekly on treatment protocol. II. Ferritin levels at study entry and every (q) 2 days on treatment protocol. III. D-dimer levels at study entry and q 2 days on treatment protocol.~OUTLINE: Patients are randomized to 1 of 2 arms.~ARM I: Patients receive dasatinib anhydrous orally (PO) once daily (QD) for 14 days in the absence of disease progression or unacceptable toxicity.~ARM II: Patients receive placebo PO QD for 14 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed up for 28 days.
This phase II trial investigates how well dasatinib works in treating patients with moderate and severe COVID-19. Dasatinib is a drug used to treat chronic leukemia which may help reduce the strong inflammation caused by COVID-19 that can damage the lungs or other organs.